Core Concepts
Nilotinib in CML patients increases the risk of metabolic syndrome and cardiovascular diseases.
Stats
"The risk for diabetes, hyperlipidemia, and cardiovascular disease is higher in patients receiving nilotinib (Tasigna) vs other tyrosine kinase inhibitors for chronic myeloid leukemia (CML)."
"The incidence rate ratios (IRR) of post-TKI diabetes were highest among patients treated with nilotinib vs imatinib and dasatinib (IRR, 3.15 for nilotinib vs imatinib; IRR, 4.97 nilotinib vs dasatinib)."
Quotes
"The present study represents the first report demonstrating a significant association between nilotinib, metabolic syndrome, and CVDs."
"To reduce the risk of CVD, it may be important to avoid nilotinib in patients with CML who have poorly controlled diabetes and hyperlipidemia."